Clinical utility and prognostic accuracy of the molecular International Prognostic Scoring System versus Revised International Prognostic Scoring System in myelodysplastic syndromes: A systematic review
International Journal of Molecular and Immuno Oncology · 05.06.2026 · 11 · 80-85
DOI: 10.25259/ijmio_3_2026 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular and Immuno Oncology, online erschienen am 05.06.2026. Verfasst von Hyomshi Bhavsar. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
The molecular International Prognostic Scoring System (IPSS-M) was introduced to integrate genomic data into Myelodysplastic syndromes risk stratification. We systematically reviewed its performance against the existing standard, the Revised International Prognostic Scoring System (IPSS-R), to evaluate its prognostic utility.
Methods
A Preferred Reporting Items for Systematic Reviews and Meta-analyses-compliant search of PubMed, Embase, and Cochrane was conducted (June 2022–December 2025) for studies validating IPSS-M. Heterogeneity was assessed using the I 2 statistic.
Results
Twelve validation studies were identified. The IPSS-M significantly outperformed the IPSS-R in prognostic discrimination, with a concordance index (C-index) for overall survival of 0.81 versus 0.71, and demonstrated high accuracy in predicting acute myeloid leukemia (AML) transformation (C-index 0.91). However, heterogeneity across cohorts regarding sequencing depth and treatment eras was noted.
Conclusion
IPSS-M provides superior risk discrimination, particularly for patients previously classified as “Intermediate” risk by IPSS-R. While promising as an advanced prognostic tool, prospective validation is required to confirm its role in guiding therapeutic interventions.
Zitieren
APA
Bhavsar, H. (2026). Clinical utility and prognostic accuracy of the molecular International Prognostic Scoring System versus Revised International Prognostic Scoring System in myelodysplastic syndromes: A systematic review. International Journal of Molecular and Immuno Oncology, 11, 80-85. https://doi.org/10.25259/ijmio_3_2026
Vancouver
Bhavsar H. Clinical utility and prognostic accuracy of the molecular International Prognostic Scoring System versus Revised International Prognostic Scoring System in myelodysplastic syndromes: A systematic review. International Journal of Molecular and Immuno Oncology. 2026;11:80-85. doi:10.25259/ijmio_3_2026
BibTeX
@article{Bhavsar2026,
author = {Bhavsar, Hyomshi},
title = {Clinical utility and prognostic accuracy of the molecular International Prognostic Scoring System versus Revised International Prognostic Scoring System in myelodysplastic syndromes: A systematic review},
journal = {International Journal of Molecular and Immuno Oncology},
year = {2026},
volume = {11},
pages = {80--85},
doi = {10.25259/ijmio_3_2026}
}
EUVIMED